Phibro Animal Health Corp. Hits New 52-Week High of $43.65

Phibro Animal Health Corp. has reached a significant milestone by hitting a new 52-week high of USD 43.65 on October 31, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 1,598 million.
Over the past year, Phibro Animal Health has demonstrated impressive growth, with a remarkable 148.43% increase in stock price compared to the S&P 500's 19.89% performance. The company has consistently reported positive results, including a staggering 2,190.43% growth in net profit as of June 25, and has achieved positive results for three consecutive quarters.

Key financial metrics highlight the company's robust position: a price-to-earnings ratio of 21.00, a dividend yield of 1.22%, and a return on equity of 18.91%. Additionally, Phibro's high institutional holdings at 100% reflect strong confidence from sophisticated investors. With a solid return on capital employed (ROCE) of 13.12% and a favorable enterprise value to capital employed ratio of 1.76, Phibro Animal Health Corp. continues to showcase its market-beating performance.